Prevention & lipidsRandomised controlled trial
Outcomes of cardiovascular screening in men aged 60–64 years: the DANCAVAS II trial
- Randomised controlled trial
- population-based
- parallel
- 1:4 randomisation
- stratified on municipality
- only control group blinded
Authors' conclusion
Invitation to a comprehensive CT-based screening for subclinical CVD did not decrease death over 7 years among men aged 60-64 years but did increase severe bleeding.
Study context
- Population
- Danish men aged 60–64 years3,720 screened (62.6%)
- Participants
- 31,268 men
- Comparison
- Invitation to cardiovascular disease (CVD) screening vs no invitation
- Invitedn = 5,946
- Controln = 25,322reference
- Primary endpoint
- All-cause mortality
- Follow-up
- Median 7.0 years
Primary result
As reported in the abstract
median 7.0 years
Hazard ratio
0.94
95% CI 0.86–1.03
P = 0.169
Events by treatment group
Invited vs Control
HR 0.94 (95% CI 0.86–1.03); P = 0.169
Further findings
| Outcome | Invited | Control | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| MACE | 10.2% | 10.6% | 0.96 (0.88–1.04) | P = 0.319 | |
| 0.512Hazard ratio (log scale) |
Safety
| Outcome | Invited | Control | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Severe bleeding | 6.0% | 5.1% | 1.18 (1.05–1.32) | P = 0.007 | |
| Severe bleeding · intracranial bleeding | 1.23 (0.96–1.58) | P = 0.097 | |||
| Severe bleeding · gastrointestinal bleeding | 1.18 (1.03–1.34) | P = 0.014 | |||
| 0.512Hazard ratio (log scale) |
Original publication
Outcomes of cardiovascular screening in men aged 60–64 years: the DANCAVAS II trial. Eur Heart J. Published 30 August 2025. doi:10.1093/eurheartj/ehaf704
Summarised from the published abstract; every number is checked against it